|Bid||9.40 x 1000|
|Ask||10.10 x 1000|
|Day's Range||9.38 - 9.84|
|52 Week Range||9.02 - 14.76|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.33|
HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reported recent business highlights and financial results for the first quarter ended March 31, 2019. “HOOKIPA’s achievements since the start of 2019 have demonstrated our ability to execute and deliver on key company goals. Also, we now have the financial strength to achieve major milestones on our journey to translate great science into clinical programs.
HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”) for development of a therapeutic hepatitis B virus (HBV) vaccine. Based on the terms of the agreement, HOOKIPA is entitled to a milestone payment from Gilead. HOOKIPA has completed the research milestone for HBV by designing and delivering 10 research-grade vectors to Gilead, along with the characterization of these vectors and delivery of a data package for the HBV program.
HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of David R. Kaufman, M.D., Ph.D., to its Board of Directors. Prior to joining the Institute, he held several leadership positions at Merck Research Laboratories, including Head of Translational Oncology, Executive Director in Clinical Oncology and Associate Director of the Merck Drug Development and Leadership Program. Dr. Kaufman is a member of the Board of Directors of the Society for Immunotherapy of Cancer (SITC), a not-for-profit medical professional society dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
Hookipa Pharma Inc. shares were barely changed in their trading debut on Thursday, after the biotech priced its initial public offering at the low end of its price range. The stock was up a penny at $14.01. The company, which is using arenavirus-based platforms to develop treatments targeting infectious diseases and cancers, sold fewer shares than expected of just 6 million to raise $84 million. It had earlier said it would sell 6.7 million shares at a price range of $14 to $16. Bank of America Merrill Lynch, SVB Leerink and RBC Capital Markets are joint bookrunners on the deal with Kempen acting as co-manager.
Hookipa Pharma Inc. is a biotech that’s using arenavirus-based platforms to develop treatments targeting infectious diseases, including Hep B, HIV and HPV.
NEW YORK, April 17, 2019 -- HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Brainsway Ltd (BWAY) will issue 2.5 million shares at $11.94 Wednesday ...